Cardiol Therapeutics (CRDL) vs Precision BioSciences (DTIL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Precision BioSciences (DTIL) over the past year, gaining 24.5% versus a gain of 10.0%. Over five years, CRDL leads with a -66.4% price change compared with -97.9% for DTIL. Precision BioSciences is the larger company by market cap ($177.5 million vs $158.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | DTIL |
|---|---|---|
| Share price | $1.30 | $6.43 |
| Market cap | $157.97M | $177.48M |
| 1-day change | -1.52% | +2.88% |
| YTD return | +38.36% | +50.24% |
| 1-year return | +24.53% | +10.04% |
| 5-year return | -66.41% | -97.87% |
| EPS (TTM) | $-0.25 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.34 | $9.62 |
| 52-week low | $0.88 | $3.53 |
| Distance from 52-week high | -44.44% | -33.16% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +543.08% | +357.23% |
| Average volume | 1.44M | 293.42K |
| Shares outstanding | 121.51M | 27.60M |
| Employees | 18 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed DTIL by 14.5 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
CRDL vs DTIL FAQ
Which is bigger, Cardiol Therapeutics or Precision BioSciences?
Precision BioSciences (DTIL) is larger, with a market capitalization of $177.48M compared with $157.97M for Cardiol Therapeutics (CRDL).
Which stock has performed better over the past year, CRDL or DTIL?
CRDL returned +24.53% over the past 12 months, compared with +10.04% for DTIL (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Precision BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.